Serologicals — Merger or Acquisition (April 2006)
37 slides from Serologicals's merger presentation, Apr 25, 2006
Slide 1: Acquisition and Q1 2006 Webcast
Serologicals Acquisition and Q1 2006 Webcast April 25, 2006 ACCELERATING GROWTH AND INNOVATION Exhibit 99.2
Slide 2: Forward-looking Statements-Reg. G-Proxy
2 Forward-looking Statements-Reg. G-Proxy In order to take advantage of the safe harbor provisions of the private securities litigation reform act of 1995, you should understand that we will be making forward-looking statements in this conference. These statements involve a number of risks and uncer
Slide 3: Millipore / Serologicals
MILLIPORE — 2teleeicals
Slide 4: Agenda
4 Agenda • Recap of Millipore strategy • Transaction overview & strategic rationale • Operational and financial impact • First quarter 2006 earnings presentation
Slide 5: Millipore's transformation is driving accelerated revenue growth and value creation
5 Millipore’s transformation is driving accelerated revenue growth and value creation • Niche provider, moderate growth Prior to 2004 • New leadership • New strategy 2005 2006+ • Better execution • New markets • Faster growth
Slide 6: Millipore strategic goals
6 Millipore strategic goals • Strengthen leadership position with biopharmaceutical customers • Become a strategic supplier in bioscience research markets • Lead industry in product quality and manufacturing effectiveness • Become a magnet for talent • Double the value of the company by 2009
Slide 7: Building on significant progress made in 2005
7 Building on significant progress made in 2005 2 divisions 21 of 34 3 $40M 40 12% Sharpened focus from 3 divisions to Senior management, new or in new roles Acquisitions and alliances Improved manufacturing effectiveness, savings by 2009 New products launched in 2005 Revenue growth in 2005
Slide 8: Agenda
8 Agenda • Recap of Millipore strategy • Transaction overview & strategic rationale • Operational and financial impact • First quarter 2006 earnings presentation
Slide 9: Transaction overview
9 Transaction overview • $31.55 per share all cash offer for all of Serologicals’ outstanding shares • Total value of transaction: approximately $1.4 billion • Transaction expected to close by June 30, 2006 • Conditions to closing – Serologicals shareholder approval – Customary regulatory approvals
Slide 10: Serologicals: a perfect strategic fit
10 Serologicals: a perfect strategic fit • Brings strategic value to both Bioscience and Bioprocess • Provides entry into rapidly growing markets • Accelerates organic revenue growth • Establishes important critical mass • Increases 2006 and 2007 non-GAAP earnings per share – transaction is signific
Slide 11: Who is Serologicals?
11 Who is Serologicals? Research 60% Celliance 40% • A leading provider of a broad range of innovative solutions that enable and facilitate drug discovery, development and production • Research Division: Deep product portfolio and leading edge products and services in rapidly growing market segments
Slide 12: Serologicals at a glance
12 Serologicals at a glance $275M 16% 57% $0.98 24% 1,700 2005 Revenues Organic revenue growth Gross margins * Earnings per share * 2005 earnings per share growth* New products launched in 2005 Source: Serologicals *Non-GAAP, GAAP reconciliation available on Serologicals website
Slide 13: Serologicals: strong track record of innovation
13 Serologicals: strong track record of innovation New Product Launches Revenue Per New Product 2003 2004 2005 $5,797 $6,600 $8,500 2005 1,700 Source: Serologicals 2004 2003 1,215
Slide 14: Complementary strengths of each company
14 Complementary strengths of each company Leader in cell culture supplements Highly productive R&D organization Strong brand and customer relationships Innovative, broad Bioscience portfolio #1 in downstream bioprocessing, lab water, and life science filtration Global direct sales force
Slide 15: Combining two dynamic and growing companies
15 Combining two dynamic and growing companies 2005 Organic Revenue Growth Rate 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% Serologicals Millipore Qiagen Invitrogen Affymetrix Sigma-Aldrich Fisher 10% 9% 6% 6% 5% 5% Source: Company Filings and Wall Street research 16%
Slide 16: Leading player in life science consumables
16 Leading player in life science consumables Sigma-Aldrich Serologicals 2005 Revenues ($ millions) 5,000 Serologicals + Millipore Millipore Qiagen Invitrogen Affymetrix Fisher* 1,266 1,198 Source: UBS 1,667 4,141 1,000 1,500 4,000 *revenue for scientific products division
Slide 17: Bioscience becomes strategic supplier
17 Bioscience becomes strategic supplier • Transforms Millipore’s Bioscience Division by immediately providing deep product offerings in high growth markets Millipore Bioscience Today Millipore + Serologicals Lab Filtration and Sample Prep 48% Service 9% Lab Water 43% Service 6% Lab Water 32% Antibo
Slide 18: Bioscience: gains leadership positions in high growth markets
18 Bioscience: gains leadership positions in high growth markets Antibody Technology Nuclear Function Multiplex Technologies Stem Cells 9% 15% 15% 15-20% Drug Discovery 14% Estimated market CAGR 2006-2011 Source: Millipore
Slide 19: Bioscience: significant geographic synergies
19 Bioscience: significant geographic synergies % of life science sales force by geography Serologicals Millipore Asia 14% South America 7% Japan 11% North America 19% Europe 49% North America 64% Europe 30% Asia 2% Japan 2% South America 2%
Slide 20: Bioprocess: only provider of cell culture and downstream separations offerings
20 Bioprocess: only provider of cell culture and downstream separations offerings Millipore Bioprocess Today Millipore + Serologicals Chromatography & Filtration 61% Components & Systems 18% Process Monitoring Tools 19% Components & Systems 15% Process Monitoring Tools 16% Chromatography & Filtratio
Slide 21: Bioprocess: increased presence in key accounts
Bioprocess: increased presence in key accounts Process development and scale-up Upstream processing Downstream purification and filtration Ongoing compliance monitoring and testing Filtration and chromatography Disposable Solutions Process Monitoring Tools Cell Culture Supplements
Slide 22: Serologicals: a perfect strategic fit
22 Bioscience 40% Bioprocess 60% Serologicals: a perfect strategic fit Bioscience 60% Bioprocess 40% Bioscience 42% Bioprocess 58% Millipore Serologicals 2006 Revenues * Combined Company *Forecasted Pro Forma revenue
Slide 23: Agenda
23 Agenda • Recap of Millipore strategy • Transaction overview & strategic rationale • Operational and financial impact • First quarter 2006 earnings presentation
Slide 24: Higher organic growth
24 Higher organic growth Organic growth, constant currency 2006* 2007** 2005 2004 2003 6% 6% 10% 8-10% 9-11% *Millipore standalone 2006 guidance **Combined company growth over pro forma 2006 revenues
Slide 25: Serologicals will improve Millipore's profitability
25 Serologicals will improve Millipore’s profitability 2005 Results Millipore Serologicals Millipore Serologicals Gross margins* EBITDA margins* 53.9% 57.0% 22.7% 24.6% * non-GAAP, as reported
Slide 26: Cost savings and synergies
26 Cost savings and synergies • $9 to $10M cost savings and synergies in 2007 – $15 to $17M in 2008 • Revenue Synergies – Geographic sales synergies – Bioprocess sales force and customer relationships – Further leverage internet as sales channel • Integration team in place led by Charlie Wagner, Cor
Slide 27: Transaction is accretive immediately
27 Transaction is accretive immediately 2006E* New $3.60-$3.75 2007E* New $3.00-$3.10 Non-GAAP EPS 2006E Old $2.90-$2.95 *combined company
Slide 28: Financing of transaction
28 Financing of transaction • Approximately $600 mm from balance sheet • Approximately $900 mm from debt • Combined cash flow will be used to re-pay debt * Previously issued 2006 cash flow from operations guidance-annualized Serologicals* Millipore* Combined $40-$45 $180-$185 $220-$230 Cash Flow fro
Slide 29: Agenda
29 Agenda • Recap of Millipore strategy • Transaction overview & strategic rationale • Operational and financial impact • First quarter 2006 earnings presentation
Slide 30: Growth of both divisions remains strong
30 Growth of both divisions remains strong • Bioscience – Strong growth in China – Continued success with new products – Sales force initiatives are working • Bioprocess – Healthy demand from biotech customers – Strong pipeline for NovAspetic products 10.0% 13.0% Bioscience Bioprocess Q1 2006 Consta
Slide 31: Q1 2006 Highlights
31 Q1 2006 Highlights • Bioprocess continues to grow rapidly • Third straight quarter of strong performance from Bioscience • Supply chain initiative generating expansion in gross margins • Acquisitions of Serologicals and Newport Bio Systems will help to fuel future growth and profitability • Conti
Slide 32: Q1 2006 GAAP results
32 Q1 2006 GAAP results Actual Dollars (In millions, except per share data) Q1 2006 Q1 2005 % Change Sales $ 268.4 $250.2 7% Gross profit 142.6 136.1 5% % of sales 53.1% 54.4% SG&A 80.9 76.7 5% % of sales 30.1% 30.7% R&D 18.4 16.1 14% % of sales 6.9 % 6.4% Operating income 41.9 42.6 (2%) % of sales
Slide 33: GAAP to Non-GAAP Reconciliation
33 GAAP to Non-GAAP Reconciliation Actual Dollars($ millions) Q1 2005 Q1 2006 Executive transition agreements 7.8 Manufacturing consolidation - 4.2 Amortization of purchased intangibles 0.7 1.4 Total non-GAAP adjustments before taxes 9.0 8.2 Tax effects of non-GAAP adjustments (2.1) (2.9) Non-GAAP n
Slide 34: Q1 2006 Non-GAAP results
34 Q1 2006 Non-GAAP results* Actual Dollars (In millions, except per share data) Q1 2006 Q1 2005 % Growth Sales $ 268.4 $250.2 7% Gross profit 147.2 136.1 8% % of sales 54.9% 54.4% SG&A 79.0 68.5 15% % of sales 29.4% 27.4% R&D 18.1 16.1 13% % of sales 6.7 % 6.4% Operating income 50.2 51.5 (3%) % of
Slide 35: Balance sheet
35 Balance sheet Cash & marketable securities $651 $141 Debt $563 $133 Accounts receivable $215 $199 DSOs 73 days 73 days Inventory $166 $139 Days of Inventory 120 days 112 days Cash flow from operations ($24) $18 $ in millions Q1 2006 Q1 2005
Slide 36: Summary
36 Summary • Transaction will transform Millipore and immediately make company stronger player in Bioscience • Bioprocess Division gains access to large upstream market • Opportunity to accelerate R&D productivity and gain key talent • Combined company will accelerate growth and profitability and cr
Slide 37: MILLIPORE
MILLIPORE